Clin Transl Sci. 2026 Mar;19(3):e70494. doi: 10.1111/cts.70494.
ABSTRACT
Circulating serum biomarkers have prognostic value in patients with advanced NSCLC, yet their potential still remains underappreciated at present. This review discusses classical approaches of biomarker data analysis, highlighting gaps, and summarizing current methodologies to evaluate the relationship between serum biomarkers and clinical outcome in advanced NSCLC. Showcased for serum biomarker data exploitation of a phase III study in advanced NSCLC patients, this review also promotes and offers perspectives on how to analyze and interpret longitudinal biomarker data using pharmacometric approaches for potential implementation into clinical practice.
PMID:41796056 | DOI:10.1111/cts.70494
